SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm

Goldberg Law PC, a national shareholder rights litigation firm, announces a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (Nasdaq: SPPI). Investors who purchased or otherwise acquired shares between February 28, 2013 and September 16, 2016 inclusive (the "Class Period") are encouraged to contact the firm in advance of the November 21, 2016 lead plaintiff motion deadline.

If you are a shareholder who suffered a loss during the Class Period, click here to participate. In addition, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm's website at, or by email at

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Complaint alleges that during the Class Period, Spectrum made false and/or misleading statements and/or failed to disclose that: the U.S. Food and Drug Administration (the "FDA") previously questioned whether the data from the 611 and 612 Studies (the names of the Phase 3 studies for apaziquone) were clinically significant; that the FDA instructed the Company in December 2012 not to submit the New Drug Application based on data from the 611 and 612 Studies; and that as a result of the above, the Company's public statements regarding the its business, operations and prospects were materially false and misleading at all relevant times. When this news was announced, shares of Spectrum fell in value, causing the investors harm.

Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.

If you liked this article you might like

Biotech Movers: Myriad Genetics, Spectrum Pharmaceuticals, Array BioPharma

Merger Buzz Drives Akorn to Top of Health Chart in April

Shortened FDA Advisory Panel Is Bad Omen for Puma Bio's Controversial Breast Cancer Drug

Biotech Premarket Movers: Spectrum, BioCryst, Curis

Spectrum Pharma, FDA and the Buried Truth About a Bladder Cancer Drug Meeting